Univariate and multivariate analysis of response to CARTr for peripheral BCR
| No. of participants = 40 . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|
| OR . | 95% CI . | P value . | OR . | 95% CI . | P value . | |
| Prior HSCT (n = 15) | 1.859 | 0.50-6.94 | .356 | 5.175 | 0.83-32.31 | .079 |
| BCR ≤3 mo after CARTi (n = 22) | 0.898 | 0.25-3.25 | .870 | 0.996 | 0.20-4.90 | .996 |
| CART product | ||||||
| Investigational CTL019 (n = 17) | REF | REF | ||||
| HuCART19 (n = 14) | 2.400 | 0.55-10.53 | .246 | 1.313 | 0.12-14.28 | .823 |
| Commercial tisagenlecleucel (n = 9) | 1.200 | 0.21-6.80 | .837 | 0.344 | 0.04-3.00 | .334 |
| Previously treated with a different CART product (n = 7) | 1.313 | 0.25-6.88 | .748 | 0.444 | 0.04-5.10 | .513 |
| Lymphodepletion prior to CARTr (n = 28) | 11.000 | 1.25-97.02 | .031 | 33.570 | 2.07-543.24 | .013 |
| No. of participants = 40 . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|
| OR . | 95% CI . | P value . | OR . | 95% CI . | P value . | |
| Prior HSCT (n = 15) | 1.859 | 0.50-6.94 | .356 | 5.175 | 0.83-32.31 | .079 |
| BCR ≤3 mo after CARTi (n = 22) | 0.898 | 0.25-3.25 | .870 | 0.996 | 0.20-4.90 | .996 |
| CART product | ||||||
| Investigational CTL019 (n = 17) | REF | REF | ||||
| HuCART19 (n = 14) | 2.400 | 0.55-10.53 | .246 | 1.313 | 0.12-14.28 | .823 |
| Commercial tisagenlecleucel (n = 9) | 1.200 | 0.21-6.80 | .837 | 0.344 | 0.04-3.00 | .334 |
| Previously treated with a different CART product (n = 7) | 1.313 | 0.25-6.88 | .748 | 0.444 | 0.04-5.10 | .513 |
| Lymphodepletion prior to CARTr (n = 28) | 11.000 | 1.25-97.02 | .031 | 33.570 | 2.07-543.24 | .013 |
REF, reference.